

SECTION 1 Mechanisms of Drug Action and Therapeutic Principles

- 1 Introduction, 2**
Susan L. Ingram and Lynn Wecker
- 2 Cellular Receptors and Drug Concentration-Response Relationships, 4**
Laura M. Bohn, James Carlton Garrison II, and JoAnn Trejo
- 3 Pharmacokinetics, 21**
Namandjé N. Bumpus and Paul F. Hollenberg
- 4 Pharmacogenetics, 41**
Emily J. Cicali, Scott A. Mosley, and Larisa H. Cavallari
- 5 Drug Discovery, Development, and Regulation, 49**
Lance R. McMahon, Samuel Obeng, Christopher R. McCurdy, James E. Barrett, and Felix J. Kim

SECTION 2 Chemical Mediators and Drugs Affecting Autonomic and Neuromuscular Synapses

- 6 Introduction to the Autonomic Nervous System, 58**
Marsha L. Pierce and Lynn Wecker

Cholinergic Drugs

- 7 Muscarinic Agonists, Cholinesterase Inhibitors, and Their Clinical Uses, 68**
Naoto Hoshi and Frederick J. Ehlert
- 8 Muscarinic Antagonists and Their Clinical Uses, 79**
Naoto Hoshi and Frederick J. Ehlert
- 9 Nicotinic Agonists and Their Clinical Uses, 84**
Marsha L. Pierce and Lynn Wecker
- 10 Neuromuscular Blocking Drugs and Nicotinic Antagonists, 89**
Marsha L. Pierce and Lynn Wecker

Adrenergic Drugs

- 11 Adrenergic Agonists and Their Clinical Uses, 95**
Javier Cuevas
- 12 Adrenergic Antagonists and Their Clinical Uses, 107**
Javier Cuevas

SECTION 3 Drug Treatment for Disorders Affecting the Central Nervous System

- 13 The Central Nervous System, 117**
Susan L. Ingram and Lynn Wecker
- 14 Drug Therapy for Alzheimer Disease and Other Cognitive Disorders/Dementias, 129**
Michael S. Jaffee, Meredith Wicklund, Benjamin A. Chapin, and Steven T. DeKosky
- 15 Pharmacotherapy of Basal Ganglia Disorders: Parkinson Disease and Huntington Disease, 136**
D. Samba Reddy and Juan R. Sanchez-Ramos

- 16 Drug Therapy for Psychoses and Bipolar Disorder, 145**
Glenn Catalano, Deborah L. Sanchez, Cory M. Klippel, and Lynn Wecker
- 17 Drug Therapy for Depression and Anxiety, 154**
Glenn Catalano, Deborah L. Sanchez, Lynn Wecker, and Greg Sullivan
- 18 Drug Therapy for the Management of Attention Deficit-Hyperactivity Disorder, 169**
D. Samba Reddy
- 19 Drug Therapy for Insomnia and the Hypersomnias, 178**
Miranda M. Lim and Lynn Wecker
- 20 Drug Therapy for Managing Obesity and Eating Disorders, 186**
Charles Rudick
- 21 Treatment of Seizure Disorders, 192**
Michael A. Rogawski
- 22 Drug Therapy for Spasticity Disorders, 207**
D. Samba Reddy
- 23 Ethanol, Other Alcohols, and Medications for Alcohol Use Disorder, 213**
Jesse D. Hinckley and Christian J. Hopfer
- 24 Psychoactive Compounds and Substance Use Disorder, 223**
Jeffrey S. Block and Rex M. Philpot

SECTION 4 Drug Therapy for Pain Management

- 25 Introduction, 237**
Susan L. Ingram
- 26 General Anesthetics, 241**
Tasha L. Welch and Jeffrey J. Pasternak
- 27 Local Anesthetics, 252**
Marina Gitman, Joshua Edwards, and Guy Weinberg
- 28 Opioid Analgesics, 260**
Susan L. Ingram and Elena E. Bagley
- 29 Nonsteroidal Antiinflammatory Drugs and Acetaminophen, 269**
Jennelle D. Richardson and Jill Fehrenbacher
- 30 Cannabinoids, 277**
Jeffrey S. Block, Rex M. Philpot, and Lynn Wecker
- 31 Drug Therapy for Migraine Headache, 284**
D. Samba Reddy

SECTION 5 Treatment of Inflammatory, Allergic and Immunologic Disorders

- 32 Drug Therapy for Gout and Hyperuricemia, 293**
Angelo L. Gaffo and Keith S. Elmslie
- 33 Pharmacological Interventions for Allergic Reactions, 298**
Annette Gilchrist and Angela Karash
- 34 Immunosuppressants for Autoimmune Disorders and Organ Transplantation, 306**
Jennifer A. Ferrante, Mythili Chunduru, and Kymberly M. Gowdy

35 Drug Therapy for Rheumatoid Arthritis, 314*Michelle J. Ormseth and Keith S. Elmslie***SECTION 6 Drug Treatment for Cardiovascular Diseases****36 Introduction to the Regulation of Cardiovascular Function, 322***Beth A. Habecker, David A. Taylor, Abdel A. Abdel-Rahman, and Steven E. Mansoor***37 Overview of Hypertension Management and Drugs That Decrease Sympathetic Tone, 328***David A. Taylor, James A. McCormick, and Abdel A. Abdel-Rahman***38 Diuretics and Drugs That Affect Volume and Electrolyte Content, 333***James A. McCormick and Abdel A. Abdel-Rahman***39 Drugs Affecting the Renin-Angiotensin-Aldosterone System, 348***Vardan T. Karamyan and Abdel A. Abdel-Rahman***40 Calcium-Channel Blockers, 354***Kelly D. Karpa and Ryan Wilson***41 Vasodilators for Hypertensive Crises, Pulmonary Hypertension, and Erectile Dysfunction, 359***David A. Tulis and David S. Middlemas***42 Treatment of Hyperlipidemias and Atherosclerotic Cardiovascular Disease, 367***Dan F. McCune, Michael T. Piascik, and Robert W. Hadley***43 Treatment of Myocardial Ischemia and Angina Pectoris, 378***David A. Taylor and J. West Paul Jr.***44 Treatment of Heart Failure, 384***Ashley N. Guillory, Michael T. Piascik, and Robert W. Hadley***45 Antiarrhythmic Drugs, 392***David A. Taylor and Stephanie W. Watts***46 Anticoagulant, Antiplatelet, and Fibrinolytic Medications, 406***Paul T. Kocis, Francis Herrmann, Kelly D. Karpa, and Kent E. Vrana***47 Drug Therapy for Hemophilia and the Deficiency Anemias, 416***David A. Taylor and Pamela E. Potter***SECTION 7 Treatment of Endocrine Disorders****48 Introduction to Endocrine Pharmacology, 424***James J. O'Donnell III***49 Treatment of Hypothalamic and Pituitary Disorders, 428***Gerald B. Call and James J. O'Donnell III***50 Diagnosis and Treatment of Adrenocorticosteroid Disorders, 437***James J. O'Donnell III and Gerald B. Call***51 Female Hormone Regulation, 446***David S. Middlemas and Julia Ousterhout***52 Androgens, Antiandrogens, and Their Clinical Uses, 462***David S. Middlemas***53 Drug Therapy for the Management of Diabetes, 469***Phillip G. Kopf and Julio A. Copello***54 Drug Therapy for the Management of Thyroid Disorders, 485***James J. O'Donnell III and Gerald B. Call***55 Calcium Regulating Hormones and Other Agents Affecting Bone, 494***James J. O'Donnell III and Gerald B. Call***SECTION 8 Chemotherapy****Infectious Diseases****56 Principles of Antimicrobial Use, 506***Rukiyah Van Dross-Anderson and Eman Soliman***57 Drugs Targeting Bacterial Cell Walls and Membranes, 521***Rukiyah Van Dross-Anderson and Daniel A. Ladin***58 Drugs Targeting Bacterial Protein Synthesis, 537***Rukiyah Van Dross-Anderson and Daniel A. Ladin***59 Drugs Targeting Bacterial DNA, 551***Rukiyah Van Dross-Anderson and Eman Soliman***60 Antimycobacterial Agents, 560***Rukiyah Van Dross-Anderson and Eman Soliman***61 Drugs Targeting Resistant Organisms, 569***Rukiyah Van Dross-Anderson and Daniel A. Ladin***Parasitic Diseases****62 Antifungal Agents, 575***Mona M. McConnaughey and J. Scott McConnaughey***63 Antimalarial and Other Antiprotozoal Agents, 585***Joseph Stone Doggett and Michael Conte***64 Anthelmintics and Ectoparasitocides, 596***Mona M. McConnaughey and J. Scott McConnaughey***Viruses****65 Antiviral Agents, 602***Susan L. Ingram, LaToya M. Griffin, and Margaret Nelson***66 Antiretroviral Drugs for HIV, 613***Amy Wecker***Cancer****67 Principles of Cancer and Antineoplastic Drug Use, 623***Robert Gruener, Yingbo Huang, John S. Lazo, and R. Stephanie Huang***68 Cytotoxic Agents, 632***Jian-Ting Zhang, Amit K. Tiwari, and Mary-Ann Bjornsti***69 Targeted Anticancer Agents, 651***Amit K. Tiwari, Jian-Ting Zhang, and Jill Marie Siegfried***70 Immunological and Cell-Based Therapies, 663***Turkan Ozturk Topcu, Iyad Kobeissi, and Ahmad Tarhini***SECTION 9 Special Considerations****71 Therapeutic Use of Hematopoietic Growth Factors, 672***Pamela E. Potter***72 Gastrointestinal Disorders and Their Treatment, 677***Phillip G. Kopf and Walter Prozialeck***73 Pharmacological Interventions for Asthma and Chronic Obstructive Pulmonary Disorders, 688***Angela Karash, Susan L. Ingram, and Annette Gilchrist***74 Dietary Supplements, Nutraceuticals, and Natural Products, 699***Robert C. Speth and Pamela E. Potter***75 Essentials of Toxicology, 706***Monica A. Valentovic, Gary O. Rankin, and Lauren M. Aleksunes***76 Therapeutic Considerations for Pregnant, Pediatric, Geriatric, and Obese Individuals, 711***Lynn Wecker, Susan L. Ingram, Margaret Nelson, and LaToya M. Griffin***Answer Keys, 716****Index, 729**